Overview

Clinical Trial of YYC301 P3 for Treatment of Osteoarthritis of the Knee

Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
A Multi-center, Double-blinded, Randomized, Active-controlled, Parallel Design, phase 3 Clinical Trial to Evaluate the Efficacy and Safety of YYC301 in Patients with Osteoarthritis of the Knee Joint
Phase:
Phase 3
Details
Lead Sponsor:
Yooyoung Pharmaceutical Co., Ltd.
Collaborator:
CliPSBnC
Treatments:
Celecoxib
Tramadol